{"id":"W3213696764","doi":"10.1182/blood-2021-147607","title":"Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; St. Paul's Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Janus kinase inhibitor; Medicine; Tolerability; Internal medicine; Janus kinase 2; Extramedullary hematopoiesis; Phases of clinical research; Janus kinase; Adverse effect; Clinical trial; Bone marrow; Haematopoiesis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001599339,0.0005476609,0.00112356,0.0001932847,0.0002637978,0.000921607,0.0003631231,0.0008125489,0.001876439],"category_scores_gemma":[0.001148343,0.000223485,0.001461035,0.0002692642,0.0003952318,0.0006412633,0.0002683697,0.00190217,0.000445626],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005393996,"about_ca_system_score_gemma":0.0005050097,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005767805,"about_ca_topic_score_gemma":0.001166058,"domain_scores_codex":[0.9995794,0.0001935598,0.00003749512,0.00006060315,0.00005863404,0.00007029095],"domain_scores_gemma":[0.9992385,0.0001602346,0.0002510159,0.00004822043,0.00005270067,0.0002494562],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6282086,0.01506406,0.0566584,0.001432261,0.003255183,0.000533546,0.0003484578,0.003334176,0.02776692,0.0002447772,0.009569639,0.253584],"study_design_scores_gemma":[0.3419519,0.4261796,0.204528,0.0002373634,0.003658265,0.002441341,0.0001876601,0.004779256,0.006886061,0.000655696,0.008375486,0.0001192937],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919713,0.004886508,0.0001815267,0.000425149,0.00007038838,0.0001987045,0.00115752,0.00003241198,0.001076624],"genre_scores_gemma":[0.9958318,0.001176051,0.0001948599,0.0004018625,0.0001141509,0.0001461051,0.001680105,0.000007501817,0.0004475005],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001876439,"threshold_uncertainty_score":0.008458257,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01345752145354221,"score_gpt":0.2540983390556299,"score_spread":0.2406408176020877,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}